Moderna (NASDAQ:MRNA) shares moved higher on Thursday, building on the previous session’s strong gains as investors focused on a key review of the company’s influenza vaccine by a U. S.

The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more ...

The panel backed the vaccine, known as mFLUSIVA, for adults aged 50 years and older, concluding that its benefits outweigh ...

Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.

Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets. RSV and flu mRNA vaccines struggle with lower durability, higher ...

The vaccine maker’s shots involve the successful Covid vaccines’ RNA technology. Health Secretary Robert F. Kennedy Jr. has broadly rejected it, canceling millions of dollars in research projects. By ...

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...

An FDA panel voted 9-0 that the benefits of Moderna’s mRNA-1010 flu vaccine outweigh risks for adults aged 50 and older.

The updated 2024-2025 mRNA COVID vaccine from Moderna does not appear to carry the same risk for myocarditis in young adults that the first mRNA COVID vaccines did, suggested research presented at the ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Moderna’s new RNA-based vaccine, mNexspike, for preventing ...